Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
Hikma Pharmaceutical said all of its businesses have continued to perform well and overall it expects revenue to grow by around 17 per cent in 2013, up from previous guidance of around 13 per cent. Across its main businesses, generics continued to benefit from strong doxycycline sales. Given the st
Read more
July 8 (Reuters) - Hikma Pharmaceuticals Plc said it expects revenue to rise 17 percent in 2013, up from its previous forecast of 13 percent, boosted by strong sales of its generic antibiotic doxycycline. The company said it expected full-year revenue of about 200 million pounds ($297.65 mi
Read moreHikma Pharmaceuticals has signed an exclusive commercialisation agreement with Theravance for Vibativ in the Middle East and North Africa (MENA). Vibativ is a bactericidal, once-daily antibiotic for bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a dang
Read moreAntofagasta: UBS reduces target price from 1140p to 1050p, while upgrading from neutral to buy. ARM Holdings: Analysts at Numis have cut their view on the shares to reduce from hold. Associated British Foods: Nomura cuts target price from 1800p to 1650p downgrading to reduce. Atkins: Jefferies u
Read moreSaid Darwazah, the Chief Executive Officer of Hikma Pharmaceuticals, has reduced his stake in the FTSE 250 company, it was announced after Thursday's close. The director, who was the Minister of Health for the Hashemite Kingdom of Jordan from 2003 to 2006, sold 188,445 shares over a period of six d
Read moreAfferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation. Amara Mining: Westhouse Securities cuts target price from 110p to 90p retaining a buy recommendation. Amlin: Westhouse Securities moves target price from 455p to 470p and upgrades to add.
Read moreRonald Goode, a non-Executive Director of Hikma Pharmaceuticals, has disposed of 5,700 shares at 983.00p each. The £56,031 sale comes less than a week after the company upgraded its 2013 revenue growth forecast following a strong start to the year. In an announcment released May 16th, the group t
Read moreShares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year". The group expects revenue to rise 13% this year, up from its previous guidance of 10%, driven by the performance of Branded and Injectables and Generics
Read more* Expects 2013 revenue to rise about 13 pct * Shares rise as much as 5 pct (Adds CEO quote, details, share movement) May 16 (Reuters) - Hikma Pharmaceuticals Plc raised its full-year revenue forecast as its generic antibiotic doxycycline generated revenue ahead of its expectations,
Read moreMay 16 (Reuters) - Hikma Pharmaceuticals Plc raised its full-year revenue forecast, saying its generic antibiotic doxycycline was generating revenue ahead of its expectations. The company said it expected group revenue to rise about 13 percent in 2013, up from previous forecast of around 10
Read moreFears over economic growth and a raft of disappointing earnings in the States weighed heavily on global markets on Wednesday, while a number of heavyweight stocks going ex-dividend dampened the FTSE 100 in London. Bank of America (BofA) was the first major US bank to miss forecasts this earnings se
Read moreHikma Pharmaceuticals was a heavy faller today after going ex-dividend and being hit by a target price cut from Jefferies, from 1,150p to 1,040p. The cut came after the group announced its plan to hold on to its global injectables business. Miners were under the weather as investors looked to inves
Read moreA number of heavyweight stocks going ex-dividend assured that London's FTSE 100 index was in the red for a fourth consecutive day on Wednesday, while concerns over the global economy continued to weigh on sentiment. Global growth fears have hit markets over the last few days after a surprise slowdo
Read morePanmure Gordon has maintained its 'buy' rating and 440p target price for supermarket group Tesco, highlighting a 'welcome shift in strategy' following the firm's full-year results. Panmure reckons that Tesco is on track in the UK and expects the recovery to "slowly emerge" this year and said that i
Read moreJefferies has cut its price target for pharmaceuticals firm Hikma from 1,150p to 1,040p after the company's decision to hold on to its global injectables business. Hikma said on Wednesday that it has seen a "significant amount of interest" in the injectables business by third parties. However, the
Read more
Last checked at